Introgen, Aventis SA deal

AVE will spin out its Gencell division as an independent company focused on angiogenesis gene therapy. AVE

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE